Therapeutic Choices in Hepatology, 2025 | AASLD

Therapeutic Choices in Hepatology, 2025

Nov 08 2025
Convention Center: Room 146B, Level 1
11:00 AM - 12:30 PM

World Class Speakers

Aparna Goel, MD
Presenter

Aparna Goel, MD

Stanford University Medical Center
Veeral Ajmera, MD
Presenter

Veeral Ajmera, MD

University of California, San Diego
Joseph K Lim, MD
Presenter

Joseph K Lim, MD

Yale University School of Medicine
Sonal Kumar, MD
Moderator

Sonal Kumar, MD
Vincent Chen, MD
Moderator

Vincent Chen, MD

University of Michigan Medical Center

Description

In this case-based program, presenters provide updates on key topics in general hepatology including: (1) steatotic liver disease, with emphasis on the treatment of MASH and considerations surrounding diagnosis and management of MetALD; (2) hepatitis B management based on the AASLD 2025 guidelines; and (3) primary sclerosing cholangitis, particularly addressing screening, use of pharmacotherapy, and drug development. Cases are used to give clinicians a real-world approach to management of these common liver diseases.

Journey Maps

Presentations

11:00 AM - 11:30 AM
Oct 09 2026
Convention Center - Room 146B, Level 1

Hepatitis B Management With the New American Association for the Study of Liver Diseases Guidelines

Joseph K Lim, MD , Presenter
Cholestatic and Autoimmune
Hepatitis
MASLD
11:30 AM - 12:00 PM
Oct 09 2026
Convention Center - Room 146B, Level 1

Management of Patients With Primary Sclerosing Cholangitis

Aparna Goel, MD , Presenter
Cholestatic and Autoimmune
Hepatitis
MASLD
12:00 PM - 12:30 PM
Oct 09 2026
Convention Center - Room 146B, Level 1

Management of MASLD and MetALD with new pharmacotherapies

Veeral Ajmera, MD , Presenter
Cholestatic and Autoimmune
Hepatitis
MASLD

Objectives

  • Discuss US Food and Drug Administration approved drugs with established or potential efficacy in MASH (resmetirom, incretin mimetics, and vitamin E), indications for use, and how to choose which agent to use in various clinical scenarios.
  • Review how to diagnose MetALD in clinical practice, selection of optimal treatments for both the metabolic dysfunction-associated and alcohol-associated components of the disease, and monitoring for response.
  • Detail key changes to the updated AASLD clinical guidelines for HBV management, including indications for treatment and liver cancer screening.
  • Describe the monitoring and management of patients with primary sclerosing cholangitis with currently available tools and potential drug development for this condition.
Chair

Sonal Kumar, MD

Chair

Vincent Chen, MD

University of Michigan Medical Center